Metabolic and Serum Lipid Effects of Methylandrostane and Methylandrostene Pyrazoles*
| Autor: | Robert H. Furman, R. Palmer Howard |
|---|---|
| Rok vydání: | 1962 |
| Předmět: |
Azoles
medicine.medical_specialty Dose Anabolism medicine.drug_class Endocrinology Diabetes and Metabolism Urinary system Clinical Biochemistry Androstane compound Biochemistry chemistry.chemical_compound Endocrinology Internal medicine medicine Humans Methyltestosterone Androsterone Chemistry Biochemistry (medical) Lipids Metabolism Androgens Pyrazoles Gonadotropin medicine.symptom Weight gain medicine.drug |
| Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 22:43-51 |
| ISSN: | 1945-7197 0021-972X |
| DOI: | 10.1210/jcem-22-1-43 |
| Popis: | Metabolic balance studies were conducted on 9 subjects given 17β-hydroxy-17α-methylandrostano (3,2-c) pyrazole, 0.5–20 mg per day orally, and on 1 given 40–80 mg in the form of an aqueous suspension injected intramuscularly. Retention of 0.67–2.70 g per day of nitrogen occurred during treatment with 2–6 mg per day orally, and there was no increase with higher dosages. Weight gain and phosphorus and potassium retention occurred with little change in calcium and with variable changes in sodium balance. The effects of intramuscular treatment were less marked. Metabolic studies on 3 subjects with 17β-hydroxy-17α-methylandrost-4-eno (3,2-c) pyrazole, 1–20 mg per day orally, indicated lesser anabolic and androgenic effects than with the androstane compound. No significant toxic manifestations were observed in 31 subjects. Although slightly increased libido was noted by hypogonadal men, no androgenic symptoms occurred in women. Symptoms were relieved in postmenopausal women and urinary gonadotropin leve... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|